文献速递自身炎症与 IgG4 相关病其他结缔组织病

IgG4相关硬脑膜炎的临床表现、治疗与结局:全国病例登记与文献综述

Clinical presentation, treatment and outcome of IgG4-related pachymeningitis: From a national case registry and literature review.
PubMed 文献 · Semin Arthritis Rheum · 2019-05-15

该研究基于单中心转诊数据发现IgG4相关疾病占炎性硬脑膜炎的10%,全国IgG4相关疾病登记中硬脑膜炎频率为4.1%。报告8例新发颅內、脊髓或两者受累病例并综述46例病理证实病例,发现多数IgG4相关硬脑膜炎不伴神经外表现,一线治疗为手术和激素,部分患者需免疫抑制剂或利妥昔单抗,且可遗留后遗症。

要点

  • IgG4相关疾病是炎性硬脑膜炎的病因之一,全国登记中硬脑膜炎频率为4.1%。
  • 多数IgG4相关硬脑膜炎不伴神经外受累,仅27%脊髓和40%颅內病变合并其他部位。
  • 一线治疗为手术和激素,18%脊髓和54%颅內病变需免疫抑制剂或利妥昔单抗。

核心结论

  • IgG4相关硬脑膜炎多不伴神经外表现,部分患者需免疫抑制剂或利妥昔单抗,且可遗留后遗症。

研究设计与样本

  • 单中心转诊区域中心评估炎性硬脑膜炎中IgG4相关疾病频率,并结合全国IgG4相关疾病病例登记及文献综述46例病理证实病例。

主要发现

  • 单中心转诊区域中心炎性硬脑膜炎中IgG4相关疾病占10%,全国IgG4相关疾病登记中硬脑膜炎频率为4.1%。
  • 报告8例新发颅內、脊髓或两者受累病例,多数不伴神经外表现。
  • 仅27%脊髓和40%颅內IgG4相关硬脑膜炎合并其他疾病定位。
  • 18%脊髓和54%颅內病变需使用免疫抑制剂或利妥昔单抗。
  • 部分患者遗留后遗症,临床和/或影像学改善可能难以获得。

关键数值与推荐

  • 炎性硬脑膜炎中IgG4相关疾病占10%(单中心转诊区域中心)。
  • 全国IgG4相关疾病登记中硬脑膜炎频率为4.1%。
  • 脊髓病变中27%、颅內病变中40%合并其他疾病定位。
  • 脊髓病变中18%、颅內病变中54%需免疫抑制剂或利妥昔单抗。

临床怎么用

  • 对炎性硬脑膜炎患者应排查IgG4相关疾病,即使无神经外表现。
  • 一线治疗可考虑手术和激素,难治者需免疫抑制剂或利妥昔单抗。
  • 需关注后遗症风险,临床和影像学改善可能困难。

局限性

  • 单中心转诊区域中心数据可能受转诊偏倚影响。
  • 文献综述病例为病理证实,可能存在选择偏倚。
  • 样本量较小,结论需更大规模研究验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Pachymeningitis is rare, either idiopathic or secondary to inflammatory disorders, after tumoral, surgical or infectious causes have been excluded. The fibroinflammatory IgG4-related disease is one of the etiologies of pachymeningitis with only few cases reported yet. From a single referral regional center, we evaluated the frequency of IgG4-related disease as the cause of inflammatory pachymeningitis in 10% of cases. From a National case registry of IgG4-related disease the pachymeningitis frequency was 4.1%. We report eight new cases with cranial, spinal or both involvements and a literature review of 46 pathological proven cases. We observed that IgG4-related pachymeningitis is in most cases not associated to extra-neurological manifestations of the disease. Only 27% of spinal and 40% of cranial IgG4-related pachymeningitis are associated with other disease localizations. First line treatment strategies included surgery and steroids. The use of immunosuppressants or rituximab was necessary in 18% of spinal and 54% of cranial localizations. Some patients remained with sequellae and clinical and/or radiological improvement can be difficult to obtain.

来源:Semin Arthritis Rheum,查看原文。版权归原作者所有。

引用

  1. Melenotte C, Seguier J, Ebbo M, et al. Clinical presentation, treatment and outcome of IgG4-related pachymeningitis: From a national case registry and literature review. Semin Arthritis Rheum. 2019. PMID: 31155444. doi:10.1016/j.semarthrit.2019.05.003

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。